Medical management of pulmonary disease caused by Mycobacterium avium complex

The current medical therapy for Mycobacterium avium complex is controversial. American Thoracic Society recommendations advocate empiric therapy with drug susceptibility testing only for clarithromycin. At National Jewish, where we mainly see cases complicated by treatment failure and drug intoleran...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Clinics in chest medicine Ročník 23; číslo 3; s. 633
Hlavní autor:	Iseman, Michael D
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 01.09.2002
Témata:	Anti-Bacterial Agents Antitubercular Agents - therapeutic use Clinical Trials as Topic Drug Therapy, Combination - therapeutic use Humans Microbial Sensitivity Tests Mycobacterium avium Complex - pathogenicity Mycobacterium avium-intracellulare Infection - drug therapy Mycobacterium avium-intracellulare Infection - microbiology Tuberculosis, Pulmonary - drug therapy Tuberculosis, Pulmonary - microbiology
ISSN:	0272-5231
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	The current medical therapy for Mycobacterium avium complex is controversial. American Thoracic Society recommendations advocate empiric therapy with drug susceptibility testing only for clarithromycin. At National Jewish, where we mainly see cases complicated by treatment failure and drug intolerance, we use in vitro susceptibility testing and therapeutic drug monitoring to optimize efficacy and reduce toxicity.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23
ISSN:	0272-5231
DOI:	10.1016/s0272-5231(02)00023-0